Is Eli Lilly's Weight Loss Empire in Trouble?
Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name Zepbound in anti-obesity (and Mounjaro in treating diabetes) that became the best-selling drug in the world in 2025. Zepbound could continue riding the wave of a fast-growing weight loss market for years, but many other companies are looking to eat Eli Lilly's lunch here. Over the past three months, several have posted strong phase 2 or phase 3 results for candidates that could eventually challenge Zepbound. Is Eli Lilly's biggest growth driver in trouble?
Image source: Getty Images.
Many pharmaceutical and biotech companies, large and small, are looking to enter this field. Significantly fewer look likely to challenge Eli Lilly seriously. Let's consider three that might be able to. First, there is , which partnered with a China-based drugmaker to develop a GLP-1 medicine called olatorepatide. Regeneron owns the rights to commercialize olatorepatide in countries outside of China. Recently, the biotech giant announced that in a phase 3 study conducted in China, patients taking this medicine achieved a mean weight loss of up to 19% after 48 weeks.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
Regeneron Pharmaceuticals Inc. wird von der Community favorisiert: Deutlich mehr Buy- als Sell-Einschätzungen.
Für Regeneron Pharmaceuticals Inc. ergibt sich ein leicht positives Potenzial, angesichts eines Kursziels von 710 € im Vergleich zu 664.4 €.
